Evidence map›Paper›PMID 41583485›Full record

ReviewFrontiers in immunology2025

Perspective of using

Ethan Perkins, Christopher Cooper, Emma Lund, Miriam Alb, Hannah Morgan, Birgit Fogal, Philip Hewitt, Alexander Mazein, Marek Ostaszewski, Katherina Sewald

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ethan PerkinsInstitute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom.
Christopher CooperImmunology & Immunotoxicology, Labcorp Early Development Laboratories Limited, Harrogate, United Kingdom.
Emma LundImmunology & Immunotoxicology, Labcorp Early Development Laboratories Limited, Harrogate, United Kingdom.
Miriam AlbUniversitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Lehrstuhl für Zelluläre Immuntherapie, Würzburg, Germany.
Hannah MorganNovartis Pharma Aktiengesellschaft (AG), Biomedical Research, Novartis Campus, Basel, Switzerland.
Birgit FogalBoehringer Ingelheim Pharmaceuticals Inc., Nonclinical Drug Safety, Ridgefield, CT, United States.
Philip HewittMerck HealthCare Kommanditgesellschaft auf Aktien (KGaA), Darmstadt, Germany.
Alexander MazeinLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.
Marek OstaszewskiLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.
Katherina SewaldFraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the TGN1412 clinical trial failure to predict cytokine release syndrome (CRS) during preclinical trials, alternative

Indexed as

Cytokine Release SyndromeCytokinesImmunotherapyAnimalsAntibodies, Monoclonal, HumanizedHumansAntibodies, Monoclonal, HumanizedCytokinesTGN-1412adverse outcome pathway (AOP)clinical relevancecytokine release syndromeimmunotoxicologymicrophysiological systemorgan on chip

Identifiers

PMID41583485
PMCPMC12827592

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.